T-cell turnover during HIV infection; production and life span of T-cells in HIV infected individuals during cART

Recruiting

Conditions: AIDS
seropositive
10047438

Registration Number: NL-OMON46926

Lead Sponsor: niversitair Medisch Centrum Utrecht

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: Not specified

Target Recruitment: 25

Inclusion Criteria

All groups:
-All study subjects have to be adults (18 years of age, or older) and sound of mind and judgement.
Study group:
-They have to be HIV-1 infected and treated with cART.
-They have to have a long-term undetectable viral load (= HIV RNA , 50 copies/ml blood)
-The number of CD4 T-cells should have increased to at least 350 cells per microliter blood.
Control group low CD4 T-cells during cART:
-They have to be HIV-1 infected and treated with cART.
-They have to have a long-term undetectable viral load (= HIV RNA , 50 copies/ml blood)
-The number of CD4 T-cells should be less than 350 cells per microliter blood.
Control group HIV-1 infected, high CD4 T-cell numbers without cART
-They have to be HIV-1 infected.
-The number of CD4 T-cells should be more than 350 cells per microliter blood.

Exclusion Criteria

-HIV-2 infection
-Participants may nog have an active infection for which anti microbial drugs are being used
-Participants may not have an active hepatitis B or C infection
-Chronic hepatisis B or C for which treatment with (peg)interferon and/or ribavirine (Note: patients with untreated chronic hepatitis B or C can be included)
-They may not use immune suppressive ot immune modulating medication
-Radiotherapy or chemotherapy in the past 2 years
-Pregnancy or breastfeeding an infant
-Participation in other studies

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The most important study parameter is the lifespan of T-cells in HIV-1 infected<br /><br>individuals that reconstitute their CD4 T-cell numbers well, compared to HIV-1<br /><br>infected individuals that do not.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>A difference in T-cell origin between immunological responders and<br /><br>non-responders<br /><br>A difference in source of the T-cells between immunological responders and<br /><br>non-responders</p><br>